Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: A 1-year randomized controlled trial

Menopause

Volumn 20, Issue 1, 2013, Pages 38-46

  Pinkerton, Joann V ^a   Archer, David F ^b   Guico Pabia, Christine J ^c   Hwang, Eunhee ^c   Cheng, Ru Fong J ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c PFIZER INC   (United States)

Author keywords

Desvenlafaxine; Efficacy; Maintenance; Menopause

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GREENE CLIMACTERIC SCALE; HOT FLUSH; HUMAN; MAINTENANCE THERAPY; PATIENT GLOBAL IMPRESSION OF CHANGE SCORE; PATIENT GLOBAL IMPRESSION SYMPTOM RATING; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASOMOTOR DISORDER;

EID: 85027951101     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318274699f     Document Type: Article

References (26)

1. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., 2011.
2. Bruck K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. In: Schonbaum E, Lomax P, eds. Thermoregulation: Physiology and Biochemistry. New York, NY: Pergamon Press Inc., 1990:55-307.
3. Stahl SM. Stahls Illustrated Antidepressants. New York, NY: Cambridge University Press, 2009.
4. Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. Am J Physiol Regul Integr Comp Physiol 2007;292:R37-R46.
5. Alfinito PD, Huselton C, Chen X, Deecher DC. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 2006;1098:71-78.
6. Deecher DC, Alfinito PD, Leventhal L, et al. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007;148:1376-1383.
7. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87.
8. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. for the Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238e1-238.e10.
9. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A doubleblind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10.
10. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo-and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20.
11. Archer DF, Pinkerton JV, Guico-Pabia C, Hwang E, Cheng RJ. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine over 1 year in women with vasomotor symptoms associated with menopause. Paper presented at: 22nd Annual Meeting of The North American Menopause Society; September 21-24, 2011; Washington, DC.
12. Pinkerton JV, Constantine G, Hwang E, Cheng RJ. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2012 Sep 24 [Epub ahead of print].
13. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29:25-31.
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industryVestrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptomsVrecommendations for clinical evaluation. Available at: www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf. Accessed October 31, 2011.
15. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. Available at: www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003348.pdf. Accessed October 31, 2011.
16. Guy W, Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:217-222.
17. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
18. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86.
19. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
20. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-6930.
21. Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008;121:159-162.
22. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
23. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:568-575.
24. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause 2007;14:223-229.
25. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-3283.
26. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274.